Authors' Affiliations: Surgery Branch and Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland.
Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11.
To evaluate whether patients with metastatic gastrointestinal adenocarcinomas refractory to chemotherapy harbor tumor-reactive cytotoxic T cells.
Expansion of CD8(+) tumor-infiltrating lymphocytes (TIL) and cancer cell lines was attempted from gastrointestinal cancer metastases in 16 consecutive patients for the study of antitumor immune recognition. Retroviral transduction of genes encoding T-cell receptors (TCR) was used to define HLA-restriction elements and specific reactivity.
TIL were expanded from metastases in all patients, and new tumor cell lines were generated in 5 patients. Autologous tumor recognition without cross-reactivity against allogeneic HLA-matched gastrointestinal tumors was found in CD8(+) TIL from 3 of these 5 patients. In a patient with gastric cancer liver metastases, the repertoire of CD8(+) TIL was dominated by cytolytic sister clones reactive to 2 out of 4 autologous cancer cell lines restricted by HLA-C0701. From the same patient, a rare CD8(+) TIL clone with a distinct TCR recognized all four cancer cell lines restricted by HLA-B4901. In a patient with bile duct cancer, two distinct antitumor cytolytic clones were isolated from a highly polyclonal CD8(+) TIL repertoire. TCRs isolated from these clones recognized epitopes restricted by HLA-A*0201. In a third patient, CD8(+) TIL reactivity was progressively lost against an autologous colon cancer cell line that displayed loss of HLA haplotype.
This study provides a basis for the development of immunotherapy for patients with advanced gastrointestinal malignancies by first establishing the presence of naturally occurring tumor-reactive CD8(+) TIL at the molecular level.
评估对化疗耐药的转移性胃肠道腺癌患者是否存在肿瘤反应性细胞毒性 T 细胞。
尝试从 16 名连续患者的胃肠道癌转移灶中扩增 CD8+肿瘤浸润淋巴细胞(TIL)和癌细胞系,以研究抗肿瘤免疫识别。使用逆转录病毒转导编码 T 细胞受体(TCR)的基因来定义 HLA 限制元件和特异性反应性。
所有患者的转移灶均扩增了 TIL,并在 5 名患者中产生了新的肿瘤细胞系。在这 5 名患者中的 3 名患者的 CD8+TIL 中发现了对自身肿瘤的特异性识别,而无交叉反应性对所有 HLA 匹配的同种异体胃肠道肿瘤。在一名患有胃癌肝转移的患者中,CD8+TIL 的 repertoire 主要由对 2 种自身癌细胞系具有细胞毒性的姐妹克隆反应,这些细胞系受 HLA-C0701 限制。从同一名患者中,一个罕见的 CD8+TIL 克隆具有独特的 TCR,可识别受 HLA-B4901 限制的所有 4 种癌细胞系。在一名胆管癌患者中,从高度多克隆的 CD8+TIL repertoire 中分离出两种不同的抗肿瘤细胞毒性克隆。从这些克隆中分离出的 TCR 识别受 HLA-A*0201 限制的表位。在第三例患者中,对显示 HLA 单倍型丢失的自身结肠癌细胞系的 CD8+TIL 反应性逐渐丧失。
本研究通过首先在分子水平上建立自然发生的肿瘤反应性 CD8+TIL 的存在,为开发治疗晚期胃肠道恶性肿瘤的免疫疗法提供了基础。